All Type of News
Diane 35 tab. team of Schering Korea having popularity
Composed of 60 pharmacy collegians from 19 different universities, Diane 35 team has been getting a big popularity from 10,000 pharmacies for their systematic nationwide-tour detailing of Diane 35 tab., Schering Korea...
Registration terms for new drugs remarkably to shorten
When the preliminary review system for the protocol of clinical studies being exercised, the new drug registration process seems to be remarkably shortened effective from 2003.
The KFDA intends to charge the review...
Gradual increase in research personnel and R&D outlays foreseeable
The Korea Industrial Technology and Promotion Association says that 40 drug makers will increase the number of research personnel to 952 persons in total this year - up 12.3% over the previous year but 0.2% decrease c...
Medical representative certification being emphasized
With more intensified competition after the full-fledged SDP function in the local pharmaceutical market, a lot of pharmaceutical firms are strengthening their marketing activities in hospital and clinic sectors with ...
Drug information based mobile service being heated
Influenced by the increasing importance of drug guidance for patients after implementation of SDP (separation of dispensing from medical practice) function, a lot of pharmacy chain industries are actively engaged in p...
14 drug companies penalized on inferior qualities of drugs.
The KFDA prosecuted 14 drug companies in charge of the inferior quality controls over their drugs and other exaggerate advertising campaigns in January.
The violation included 7 companies on no tests of pharmaceuti...
Pharmacy and medical institutes on alert to WTO opening policy.
When the new WTO policy launches in 2005 the pharmacy and medical service markets seem to be open to the overseas, which calls for an urgent measure to cope with new environmental changes in overall governmental level...
Fostering program required for domestically developed new drugs.
4 new drugs have been developed by purely domestic research and development sources in Korea, but the rigid NHI pricing policy, taking too long period of its approval and price determination, has played as a serious b...
KFDA to raise preliminary review fees for clinical studies.
The KFDA newly adopted the authorization system for the protocol of clinical studies, and plans to have its explanatory meeting for the R&D responsible members of the respective pharmaceutical firms at the KPMA audito...
Delayed notice of non-bioequivalence test items in dispute
The Korean Pharmaceutical Association (KPA) has recently contended that although the drug items subject to the bioequivalence tests were already designated by the Korean Food and Drug Administration (KFDA), its delaye...
